NCT02073812View on ClinicalTrials.gov

Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Healthy Subjects
Interventions
DRUG

RPX7009 and RPX2014

The study is designed to enroll approximately 25 healthy subjects. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Carbavance (RPX7009/RPX2014)

Trial Locations (1)

85006

Pulmonary Associates, Phoenix

All Listed Sponsors
lead

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

INDUSTRY

NCT02073812 - Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter